Physician profile
Amy E Balka
NPI 1750344891
$354.32
in general payments reported to CMS, 2019-2025
11 companies · $44.20 in 2025
The $44.20 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.33 · 2020: $60.43 · 2021: $48.50 · 2022: $41.76 · 2023: $35.04 · 2024: $51.06 · 2025: $44.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $58.71 | 2022-2025 | |
| Novo Nordisk INC | $46.11 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $42.65 | 2019-2021 | |
| Pfizer INC. | $41.47 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $37.63 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $29.85 | 2024 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.56 | 2019 | |
| Stryker Corporation | $27.25 | 2025 | Smart Toe, Fixos |
| Lilly USA, LLC | $15.67 | 2020 | |
| Glaxosmithkline, LLC. | $14.78 | 2023 | Arexvy, Shingrix |
| Astellas Pharma US INC | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Balka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.